SUPN ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Supernus Pharmaceuticals, Inc. Shareholders Who Lost Money — Neutral
SUPN Accesswire — April 29, 2025NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.

Did West Pharmaceutical Services, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - WST — Neutral
WST Accesswire — April 29, 2025NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.

Lost Money on Geron Corporation (GERN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky — Neutral
GERN Accesswire — April 29, 2025NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=145944&wire=1 or contact Joseph E. Levi, Esq.

Everus Construction Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ECG — Neutral
ECG Accesswire — April 29, 2025NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Everus Construction Group, Inc. (NYSE:ECG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/everus-construction-group-inc-lawsuit-submission-form?prid=145941&wire=1 or contact Joseph E. Levi, Esq.

Investors in SoundHound AI, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - SOUN — Neutral
SOUN Accesswire — April 29, 2025NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your SoundHound AI, Inc. (NASDAQ:SOUN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/soundhound-ai-inc-lawsuit-submission-form?prid=145942&wire=1 or contact Joseph E. Levi, Esq.

Bowman Announces Attendance at May Investor Conferences — Neutral
BWMN Business Wire — April 29, 2025RESTON, Va.--(BUSINESS WIRE)-- #BetterWithBowman--Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, announced it will participate in three investor conferences in May: BofA Securities Industrials, Transportation & Airlines Key Leaders Conference, held May 13-15 in New York, NY 25th Annual B. Riley Securities Investor Conference, held May 22-23 in Beverly Hills, CA 22nd Annual Craig-Hallum Institutional Investor Conference, held May 28 in Minneapolis, MN A.

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy — Neutral
PROF GlobeNewsWire — April 29, 2025– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the …

CINCINNATI, April 29, 2025 (GLOBE NEWSWIRE) -- Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, reported financial results for the thirteen weeks ended March 29, 2025.

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution — Neutral
KNSA GlobeNewsWire — April 29, 2025– ARCALYST ® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –

WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025.

ZenaTech's ZenaDrone Subsidiary Will Showcase its Drones to US Defense Potential Customers at Major Upcoming Conferences — Neutral
ZENA GlobeNewsWire — April 29, 2025VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces today it will showcase its ZenaDrone 1000 and IQ series drones as an exhibitor at several prominent upcoming US defense and technology conferences starting this week. These events will be an important opportunity to engage one-on-one with potential customers, key stakeholders, and industry leaders across the US military and government sectors as well as in the mining sector.

Granite Point Mortgage Trust Inc. Announces Dates for First Quarter 2025 Earnings Release and Conference Call and Provides Business Update — Neutral
GPMT Business Wire — April 29, 2025NEW YORK--(BUSINESS WIRE)--Granite Point Mortgage Trust Inc. Announces Dates for First Quarter 2025 Earnings Release and Conference Call and Provides Business Update.

New Era Helium Receives Approval for Approximately 120 Miles of Rights-of-Way to Support Midstream Business Unit and Responsibly Sourced Gas Initiatives within the Pecos Slope, Permian Basin — Neutral
NEHC Business Wire — April 29, 2025MIDLAND, Texas--(BUSINESS WIRE)--New Era Helium, Inc. (Nasdaq: NEHC) (“NEH” or the “Company”), an exploration and production (E&P) company sourcing helium from natural gas reserves in the Permian Basin, today announced it will commence its infrastructure buildout within the Pecos Slope Field within the next two weeks as it has secured approval for approximately 120 miles of Rights-of-Way (ROW) in collaboration with the U.S. Department of the Interior's Bureau of Land Management (BLM) Pecos.

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report — Neutral
AGEN Business Wire — April 29, 2025LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID:.

Nursing in 2025: No Relief in Sight as Burnout, Stress & Short Staffing Persist — Neutral
CCRN Business Wire — April 29, 2025BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country and FAU release 2025 nursing study, revealing high stress, burnout, and staffing shortages impacting nurses nationwide.

Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care — Neutral
HIMS Business Wire — April 29, 2025SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. As a first step, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy® and a Hims & Hers membership, which includes access to 24/7 care,.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.

World Acceptance Corporation Reports Fiscal 2025 Fourth Quarter Results — Neutral
WRLD Business Wire — April 29, 2025GREENVILLE, S.C.--(BUSINESS WIRE)---- $WRLD--World Acceptance Corporation (NASDAQ: WRLD) today reported financial results for its fourth quarter of fiscal 2025. Fourth fiscal quarter highlights During its fourth fiscal quarter, World Acceptance Corporation achieved improved earnings driven by an increase in our tax preparation revenue. The quarter also benefited from a partial forfeiture of our performance-based restricted shares granted in 2018 that had a $16.35 earnings per share (EPS) performance targ.

Starbucks Says It's Making Progress on Quest to Fulfill Orders More Quickly — Positive
SBUX WSJ — April 29, 2025The coffee chain says its new tech can cut in-store wait times by two minutes, as it has been struggling with slowing sales.

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors — Neutral
CRDL Newsfile Corp — April 29, 2025Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D.
